This book is a unique overview of insights on the genetic basis of anti-diabetic activity, chemistry, physiology, biotechnology, mode-of-action, as well as cellular mechanisms of anti-diabetic secondary metabolites from medicinal plants. The World Health Organization estimated that 80% of the populations of developing countries rely on traditional medicines, mostly plant drugs, for their primary health care needs. There is an increasing demand for medicinal plants having anti-diabetic potential in both developing and developed countries. The expanding trade in medicinal plants has serious implications on the survival of several plant species, with many under threat to become extinct. This book describes various approaches to conserve these genetic resources. It discusses the whole spectrum of biotechnological tools from micro-propagation for large-scale multiplication, cell-culture techniques to the biosynthesis and enhancement of pharmaceutical compounds in the plants. It also discusses the genetic transformation as well as short- to long-term conservation of plant genetic resources via synthetic seed production and cryopreservation, respectively. The book is enriched with expert contributions from across the globe. This reference book is useful for researchers in the pharmaceutical and biotechnological industries, medicinal chemists, biochemists, botanists, molecular biologists, academicians, students as well as diabetic patients, traditional medicine practitioners, scientists in medicinal and aromatic plants, Ayurveda, Siddha, Unani and other traditional medical practitioners.

Thoroughly updated and revised
A clearly structured and colourfully illustrated guide to the differential diagnosis of symptoms commonly seen by community pharmacists.
Organised by body system, each chapter begins with a system overview and a brief guide to history-taking.
Each symptom or condition examined according to background; prevalence; aetiology; arriving at a differential diagnosis; questions to ask the patient, and conditions to eliminate.

From reviews of the first edition
'Paul Rutter's timely book provides a well-structured guide to making differential diagnoses ... The comprehensive text is easy to read and there are many excellent illustrations. ... All community pharmacists - whatever their experience - will find this book an excellent continuing professional development resource. I recommend it.' "The Pharmaceutical Journal"

This volume assembles and integrates the wealth of diverse information that is now accumulating in this burgeoning field. The existing and potential therapeutic applications of targeting CA cover a remarkably wide-range of diseases and disorders and have generated increasing and extensive interest in recent years. Its inter-disciplinary approach embraces both the most up-to-date therapeutic application of CA-targeting and the latest research data that will provide a platform for the development of novel applications. The interested audience comprises scientists and clinicians from many relevant disciplines within science and medicine.

Offering a valuable resource for medical and other historians, this book explores the processes by which pharmacy in Britain and its colonies separated from medicine and made the transition from trade to profession during the nineteenth and twentieth centuries. When the Pharmaceutical Society of Great Britain was founded in 1841, its founders considered pharmacy to be a branch of medicine. However, the 1852 Pharmacy Act made the exclusion of pharmacists from the medical profession inevitable, and in 1864 the General Medical Council decided that pharmacy legislation was best left to pharmacists themselves. Yet across the Empire, pharmacy struggled to establish itself as an autonomous profession, with doctors in many colonies reluctant to surrender control over pharmacy. In this book the author traces the professionalization of pharmacy by exploring issues including collective action by pharmacists, the role of the state, the passage of legislation, the extension of education, and its separation from medicine. The author considers the extent to which the British model of pharmacy shaped pharmacy in the Empire, exploring the situation in the Divisions of Empire where the 1914 British Pharmacopoeia applied: Canada, the West Indies, the Mediterranean colonies, the colonies in West and South Africa, India and the Eastern colonies, Australia, New Zealand, and the Western Pacific Islands. This insightful and wide-ranging book offers a unique history of British pharmaceutical policy and practice within the colonial world, and provides a firm foundation for further studies in this under-researched aspect of the history of medicine.

This book introduces "network pharmacology" as an emerging frontier subject of systematic drug research in the era of artificial intelligence and big data. Network Pharmacology is an original subject of fusion system biology, bioinformatics, network science and other related disciplines. It emphasizes on starting from the overall perspective of the system level and biological networks, the analysis of the laws of molecular association between drugs and their treatment objects, reveals the systematic pharmacological mechanisms of drugs, and guides the research and development of new drugs and clinical diagnosis and treatment. After it was proposed, network pharmacology has been paid attention by researchers, and it has been rapidly developed and widely used. In order to systematically reveal the biological basis of diagnosis and treatment in traditional Chinese medicine and modern medicine, we proposed a new concept of "network target" for the first time, which has become the core theory of "network pharmacology". The core principle of a network target is to construct a biological network that can be used to decipher complex diseases. The network is then used as the therapeutic target, to which multicomponent remedies are applied. This book mainly includes four parts: 1) The concept and theory of network pharmacology; 2) Common analysis methods, databases and software in network pharmacological research; 3) Typical cases of traditional Chinese medicine modernization and modern drug research based on network pharmacology; 4) Network pharmacology practice process based on drugs and diseases.

This open access book describes strategies and experiences of highly skilled professionals in improving oncology care worldwide. The book is structured into three main sections with several chapters each, reflecting the authors' individual, real-life experiences. It explores ways to improve oncology education and scientific training, how to set up and run a clinical research facility ethically and efficiently in low- and middle-income settings, addressing the challenges that the workforce encounters in the real world. The main challenges of today's oncologists seem to be the ever-growing patient care and administrative workload and the risk of burn-out. What are the best strategies to maintain a healthy work-life for the benefit of the patients, the physicians and society, taking into account the different needs, depending on factors like peace, social and gender equality? This book addresses oncologists all over the world and their allies throughout the associated industries to highlight the importance of shared and sustainable education, clinical research and global cancer care.

Numerous phenomenal advances have been made towards understanding the role of neurotransmitters in the pathophysiology of neurological disorders, and these have resulted in a large number of novel molecules with the potential to revolutionize the treatment and prevention of such disorders. This book provides a comprehensive and detailed explanation of brain neurotransmitters and their receptors and associated channels. It includes a basic introduction, and also discusses the functions and recent advances and their pharmacology, highlighting the role of various computer aided drug design (CADD) strategies for the development of therapeutic ligands to modulate these receptors/ion channels. Written in an easy-to-read style, it is intended for neuroscience and pharmaceutical students and researchers working in the area of brain neurotransmitters.

This book presents recent advances in the use of ionic liquids in medicine and pharmaceutics with particular emphasis on addressing critical pharmaceutical challenges, including the low solubility, polymorphism, and bioavailability of drugs. It also provides insights into the development of the biologically functionalized ionic liquids suitable for medical and pharmaceutical applications. Ionic liquids have been used as potential solvents or materials in the fields of pharmaceutical drug delivery and formulations because of their unique and tunable physicochemical and biological properties. Readers find explanations of the diverse approaches to the application of ionic liquids in drug solubility, active pharmaceutical ingredient (API) formulation, and drug delivery systems, such as topical, transdermal, and oral delivery, with particular emphasis on recent developments. Particular attention is given to the development of ionic liquid-assisted effective drug delivery techniques for sparingly soluble or insoluble drug molecules. This book also discusses the biological activities of ionic liquids for possible applications in drug formulation and drug delivery systems. Scientists in disciplines such as chemistry, biology, and pharmaceutics find this book instructive and informative for developing ionic liquid-based drug formulations or drug delivery systems.

The book concentrates on powder flow properties, their measurement and applications. These topics are explained starting from the interactions between individual particles up to the design of silos. A wide range of problems are discussed - such as flow obstructions, segregation, and vibrations. The goal is to provide a deeper understanding of the powder flow, and to show practical solutions.

From "pharma bros" to everday household budgets, just how did the pharmaceutical industry betray its own history-and how can it return to its tradition of care? It's an unfortunate and life-threatening fact: one in five Americans has skipped vital prescriptions simply because of the cost. These choices are being made even though we have reached a point in the conveyance of medical options where cancers can be cured and sight restored for those blinded by rare genetic disorders. How, in this time of such advancements, did we reach a point, where people cannot afford the very things that could save their lives? As the COVID-19 global pandemic has pointed out, we need the leadership of scientists, researchers, public health officials and lawmakers alike to guide us through not only in times of a global health crisis, but also during far more mundane times. For the first time in decades, people from all walks of life face the same need for medicine. It is time to discuss the tough questions about drug pricing in an open, honest and, hopefully, transparent manner. But first we must understand how we, as a society, got here. Medicines are arguably the most highly regulated-and cost-inflated-products in the United States. The discovery, development, manufacturing and distribution of medicines is carried out by an ever more complex and crowded set of industries, each playing a part in a larger "pharmaceutical enterprise" seeking to maximize profits. But this was not always the case. The Price of Health is the reveals the story of how the pharmaceutical enterprise took shape and led to the present crisis. The reputation of the pharmaceutical industry is suffering from self-inflicted wounds and its continued viability, indeed survival, is increasingly questioned. Yet the drug makers do not shoulder all the blame or responsibility for the current price crisis. Deeply researched, The Price of Health gives us hope as to how we can still right the ship, even amidst the roiling storm of a global pandemic. How have medicines have been made and distributed to consumers throughout the years? What sea of changes that have contributed to rising costs? Some individuals, actions, and systems will be familiar, others may surprise. Yet the combined implications of these actions for will be surprising and at times shocking to both industry professionals and average Americans alike. Like so much else in human history, the history of the pharmaceutical enterprise is populated mostly by well-intended and even noble individuals and organizations. Each contributed to the formation or maintenance of structures meant to improve the quality and quantity of life through the development and distribution of medicines. And yet systems originally created to do good have often been subverted in ways contrary to the motivations of their creators. Only by understanding this disconnect can we better tackle the underlying problems of the industry head on, preventing foreseeable, and thus avoidable, medical calamities to come.

Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices covers the modern micro and nanotechnologies used for diagnosis, drug delivery, and theranostics using micro, nano, and implantable systems. In-depth coverage of all aspects of disease treatment is included. In addition, the book covers cutting-edge research and technology that will help readers gain knowledge of novel approaches and their applications to improve drug/agent specificity for diagnosis and efficient disease treatment. It is a comprehensive guide for medical specialists, the pharmaceutical-industry, and academic researchers discussing the impact of nanotechnology on diagnosis, drug delivery, and theranostics.

This fourth volume describes 256 species of medicinal plants from 5 families, which are commonly used in Chinese medicine. The most important species are Agrimonia pilosa, Amygdalus persica, Armeniaca mume, Armeniaca vulgaris, Armeniaca sibirica, Chaenomeles sinensis, Eriobotrya japonica of Rosaceae; Chimonanthus praecox of Calycanthaceae)Albizia julibrissin, Archidendron clypearia, Entada phaseoloides, Bauhinia championii of Mimosoideae; Caesalpinia sappan, Cassia tora, Gleditsia sinensis of Caesalpiniaceae; Abrus cantoniensis, Astragalus membranaceus, Astragalus membranaceus, Dalbergia odorifera, Desmodium caudatum, Desmodium styracifolium, Erythrina variegata, Euchresta japonica, Flemingia prostrata, Glycyrrhiza uralensis, Glycyrrhiza inflata, Glycyrrhiza glabra, Lablab purpureus, Sophora japonica and Spatholobus suberectus of Butterflyaceae. In each specie, it introduces the scientific names, medicinal names, morphologies, habitats, distributions, acquisition and processing methods of these medicinal plants, the content of medicinal properties, therapeutic effects, usage and dosage of these medicinal plants, and attaches unedited color pictures and pictures of part herbal medicines of each species. This book series has 10 volumes in total, which covers over 2000 kinds of Chinese medicines that are commonly used. These volumes not only introduce the efficacy function and some prescriptions of the medicines, but also introduce the biological characteristics of them in detail with clear photos of the habitats, so that readers can identify them in the field. Apart from the growing environment, the books expound the distribution areas and other information to facilitate researches and other applications. The volumes are targeted at readers of general interests and it is also of high referential value for scientific researcher and teachers. It can be used as a guide to researchers, clinical doctors, and students in the department of pharmaceutics and traditional Chinese medicine.

Zur Einordnung der einzelnen Wirkstoffe wird auch die PRISCUS-Liste berücksichtigt. Die A-Z Struktur, in der die Psychopharmaka-Profile aufgelistet sind, ermöglicht eine gezielte Suche und schnelles Finden der gwünschten Information. Die Listen geordnet nach Handelsnamen und nach Wirkstoffen unterstützt ebenfalls das schnelle Nachschlagen. Ein praktisches Taschenbuch zum schnellen Nachschlagen für Pflegefachkräfte in stationären und ambulanten Pflegeeinrichtungen. Aber auch Krankenpflegekräfte, Hausärzte und Medizinische Fachangestellte können von diesem übersichtlichen Nachschlagewerk profitieren. Für einen verantwortungsvollen und bewussten Umgang mit Psychopharmaka in der Betreuung älterer Menschen. Erhebungen zeigen, dass oft zu schnell und zu viele Psychopharmaka an ältere Menschen verabreicht werden. Insbesondere pflegebedürftige Menschen haben unter den Folgeerscheinungen wie z.B. Desorientierung, erhöhte Sturzgefahr, Immobilität zu leiden. Diese Einschränkungen zeigen sich im Alltag und können meist nur durch beobachtende Pflegekräfte erkannt und an den Arzt weitergetragen werden. Dieses praktische Taschenbuch vereint wichtiges Basiswissen häufiger Psychopharmaka und deren Wirkung bzw. unerwünschten Nebenwirkungen bei älteren Menschen. Der Fokus liegt auf den Fakten, die in der Pflege und Betreuung relevant sind, wie z.B. ... Durch das Wissen können Veränderungen bzw. Verschlechterungen des Gesundheitszustandes Pflegebedürftiger besser eingeschätzt und als mögliche Wechselwirkung oder Folgeerscheinung eines Medikaments erkannt werden. Dieses Wissen befähigt Pflegekräfte in der Kommunikation mit dem Arzt, besser auf negative Wechselwirkungen und Folgeerscheinungen einer eingestellten Medikation aufmerksam zu machen und nach einer Optimierung der Dosierung und Einstellung im Sinne des Senioren zu suchen. Neben der Aufklärung über Wirkung und Nebenwirkung einzelner Medikamente werden alternative Angebote aus z.B. der Basalen Stimulation, Seelsorge, Physiotherapie, Ergotherapie, Aromatherapie vorgestellt, mit denen Therapieziele ebenso erreicht werden können. Durch das fundierte Hintergrundwissen aus diesem Buch gelingt es Pflegekräften auf Augenhöhe mit dem Arzt zu kommunizieren, negative Wechselwirkungen schneller zu erkennen und somit dazu beizutragen, dass diese reduziert werden und weniger Psychopharmaka verabreicht werden, was immer die Lebensqualität der betroffenen Senioren erhöht.

This third volume describes 226 species of 32 families of medicinal plants, which are commonly used in Chinese medicine. The most important species are Aquilaria sinensis and Daphne genkwa of Thymelaeaceae; Benincasa hispida, Siraitia grosvenorii, Trichosanthes kirilowii and Trichosanthes rosthornii of Cucurbitaceae; Camellia sinensis of Theaceae; Cleistocalyx operculatus, Eugenia caryophyllata and Rhodomyrtus tomentosa of Myrtaceae; Osbeckia chinensis of Melastomataceae; Quisqualis indica and Terminalia chebula of Combretaceae; Hypericum japonicum of Hypericaceae; Microcos paniculata of Tiliaceae; Hibiscus mutabilis of Malvaceae; Croton crassifolius, C. lachnocarpus, C. tiglium, Euphorbia humifusa, E. lathyris, E. pekinensis, Phyllanthus emblica and Sauropus spatulifolius of Euphorbiaceae. In each specie, it introduces the scientific names, medicinal names, morphologies, habitats, distributions, acquisition and processing methods of these medicinal plants, the content of medicinal properties, therapeutic effects, usage and dosage of these medicinal plants, and attaches unedited color pictures and pictures of part herbal medicines of each species. This book series has 10 volumes in total, which covers over 2000 kinds of Chinese medicines that are commonly used. These volumes not only introduce the efficacy function and some prescriptions of the medicines, but also introduce the biological characteristics of them in detail with clear photos of the habitats, so that readers can identify them in the field. Apart from the growing environment, the books expound the distribution areas and other information to facilitate researches and other applications. The volumes are targeted at readers of general interests and it is also of high referential value for scientific researcher and teachers. It can be used as a guide to researchers, clinical doctors, and students in the department of pharmaceutics and traditional Chinese medicine.

The book concentrates on powder flow properties, their measurement and applications. These topics are explained starting from the interactions between individual particles up to the design of silos. A wide range of problems are discussed - such as flow obstructions, segregation, and vibrations. The goal is to provide a deeper understanding of the powder flow, and to show practical solutions.

Cannabis is one of the oldest cultivated plants dating back 12,000 years and demonstrates medicinal properties including immune support, anti-inflammatory effects, and cancer-fighting potential. As cannabis receives regulatory approval in the United States, clinicians will need guidelines to prescribe medical marijuana for various health conditions. This book presents information to healthcare professionals focusing on medical cannabis. It is a science-based overview providing clinical recommendations and dosing guidelines for practitioners to advise patients appropriately. Features: Discusses the endocannabinoid system role in homeostasis, pain control, and regulatory function in health and disease Advises clinicians on cannabis use in patients with cancer; cardiovascular, brain, and liver function; mood disorders; and patients receiving palliative care Includes information on cannabis nutrition as well as the cannabis microbiome Features information on cannabis quality control for safe and effective delivery Cannabis: A Clinician's Guide is written for clinicians providing a resource guide to help them assess the medicinal value of cannabis, answer patient and consumer questions, and recommend its use optimally. The book is divided into three sections covering cannabis science, use in clinical practice, and regulations and standards. It includes practical information on dosing guidelines and dispensary insights, personal cannabis stories, and an in depth look at the nutritional benefits of cannabis and how to use it in daily life. From the Author: "As a clinical nutritionist, I have been involved in the use of cannabis since 1981 while researching diabetes in India. Ayurvedic medicine listed cannabis as a beneficial herb with curing properties. In 1983, a Chinese medicine doctor in the Peoples Republic of China gave me a cannabis herbal supplement for sleep that he claimed Chairman Mao took regularly. Upon returning to the United States, no one would even talk to me about cannabis because of its Schedule I status. During an Antioxidants class taught for Everglades University, I included information on cannabis, but was restricted from including it in the course description. Cannabis: A Clinician's Guide unveils deceit on this herbal medicine used for thousands of years providing insight into the science behind its use and how to incorporate cannabis into daily life, especially for those suffering from neurological disorders, cancer, and mood disorders."

This book provides the first diverse and multifaceted textual and cartographic overview of natural curative resources of mineral waters and peloids in Russia. In a readily understandable way the book informs about the genesis, history of exploration and geographical features of water springs, their properties and use as healing springs, as well as specifics and prospect of their contemporary use. The monograph features numerous color illustrations and photos and is oriented toward a general audience but also appeals to geographers, environmental and public health workers and other specialists interested in environmental and public health issues.

This book is an excellent review of health promotion in the context of the pharmacy practice. Since the publication of the first edition, major changes have taken place in the involvement of pharmacists in health promotion. Health promotion is now a core role for community (retail) pharmacist and health promotion is now taught as a core-subject in all schools of pharmacy. The misuse of drugs is now a greater problem than ever before and pharmacists need updating in this area. Pharmacists have the monopoly on sales of nicotine replacement therapy and are now the key group involved in opportunistic advice to those who want to stop smoking. The book aims to inform pharmacists about all major health issues such as the effects of smoking; nutrition; exercise; oral health; family planning; woman's' health; child health; travel health; alcohol and mental health. The authors show pharmacists what they can achieve in health promotion stressing the social and behavioural aspects. There are key chapters on the major health challenges facing the 21 Century, the social inequalities of health and health care, problems in achieving behavioural change, and the importance of good communication especially about risks.

This encyclopedia scientifically describes 121 vegetable oils and fats. In addition to conventional oils, the book also covers lesser-known oils such as Amaranth, Chia, prickly pear, and quinoa. Author pays particular attention to root plants, extraction, and the ingredients included in information nutritionally relevant to fatty acid patterns. Applications in pharmacology, medicine, cosmetics and technology, as well as possible adverse effects, are discussed. The thoroughly researched reference book includes detailed descriptions along with the latest research results and methods.

This volume provides a complete update of all the materials in prior volumes on the subject (including current directories to testing labs and other support establishments worldwide), while adding substantial new material on the following topics: * The history of CROs, including snapshots of CROs and a genealogy chart making clear where they came from and where they went. * Study directors and principal investigators. * The nuts and bolts of study performance. * Electronic reporting requirements - SEND and eCTD (required for NDA, BLA, ANDA, and IND submissions). * Consultants and their roles. * An expanded examination of common problems and their solutions. This book boasts complete directories to the global universe of operating labs - where they are, how to contact them, and what they do (including special capabilities). Additionally, checklists for qualifying labs and manufacturing facilities - and for auditing studies and projects at such facilities - are included. It is directed at those in industry (specifically directed at those working for companies using CRO services) but will also be of interest to scientists or administrators working in research organizations themselves. In this case, the contents of this new work are essential to the target reader because the work, regulations, and actors (CROs) have evolved and changed at a rapid pace in the 10 years since the earlier volume that the author published. Likewise, the companies using these services have come to all be almost completely dependent on outsourcing. The earlier texts remain the only source of their kind (paper or electronic) on the field and the only noncommercial guide to the global industry and this volume provides a complete update.

Am Rande des Third International Meeting on Boron Chemistry (IMEBORON 111, Munchen und Ettal 1976) wurde ich gelegentlich auf eine Veroeffentlichung*) angesprochen, in der ich einige Jahre zuvor, in begrenztem Umfang, uber Anwendungen und Wirkungen von Borverbindungen aus pharmazeutisch-chemischer Sicht referiert hatte. Bei diesen Gesprachen wurde deutlich, dass eine Nachfrage nach einem Gesamtuberblick uber die interdisziplinar breit verstreuten und oft "versteckten" Publikationen uber experimentelle und praktische Anwendungen von Borverbindungen in Arznei- mittelchemie, Medizin und den ubrigen Biowissenschaften besteht und dass eine umfassende Dar- stellung dieses Aspekts der Bor-Chemie eine Lucke in der UEbersichtsliteratur fullen wurde. Die entscheidende Anregung gab schliesslich Prof. Dr. Kurt Niedenzu (University of Kentucky, Lexington, USA) als verantwortlicher wissenschaftlicher Koordinator der "Bor"-Erganzungsbande zum Gmelin Handbuch der Anorganischen Chemie durch den Vorschlag, die seit Erscheinen jener Veroeffentlichung erheblich angewachsene Literatursammlung doch einem groesseren Interessenten- kreis zuganglich zu machen und ein geschlossenes Kapitel uber Borverbindungen unter biologisch- medizinisch-pharmazeutisch-chemischen Gesichtspunkten fur einen der Bande abzufassen. Wahrend der Arbeit an diesem Kapitel stellte sich heraus, dass der geplante Umfang wiederum nur eine partielle Wiedergabe des vorliegenden Materials ermoeglichen wurde. So kam es zur UEbereinkunft mit dem Gmelin-Institut (Frankfurt am Main), dem Thema eine eigene Monographie - unabhangig vom Gmelin Handbuch, aber als Erganzung zur gesamten Bor-Reihe - zu widmen. Dabei sollte in Erweiterung des ursprunglichen Konzepts die Toxikologie der Borverbindungen noch ausfuhrlicher mitberuck- sichtigt werden.

This book is the first text to provide a comprehensive assessment of the application of fundamental principles of dissolution and drug release testing to poorly soluble compounds and formulations. Such drug products are, vis-a-vis their physical and chemical properties, inherently incompatible with aqueous dissolution. However, dissolution methods are required for product development and selection, as well as for the fulfillment of regulatory obligations with respect to biopharmaceutical assessment and product quality understanding. The percentage of poorly soluble drugs, defined in classes 2 and 4 of the Biopharmaceutics Classification System (BCS), has significantly increased in the modern pharmaceutical development pipeline. This book provides a thorough exposition of general method development strategies for such drugs, including instrumentation and media selection, the use of compendial and non-compendial techniques in product development, and phase-appropriate approaches to dissolution development. Emerging topics in the field of dissolution are also discussed, including biorelevant and biphasic dissolution, the use on enzymes in dissolution testing, dissolution of suspensions, and drug release of non-oral products. Of particular interest to the industrial pharmaceutical professional, a brief overview of the formulation and solubilization techniques employed in the development of BCS class 2 and 4 drugs to overcome solubility challenges is provided and is complemented by a collection of chapters that survey the approaches and considerations in developing dissolution methodologies for enabling drug delivery technologies, including nanosuspensions, lipid-based formulations, and stabilized amorphous drug formulations.

Die Dunnschichtchromatographie (DC) ist besonders in der pharmazeutischen Analytik und der Lebensmittelanalytik eine haufig durchgefuhrte Trenntechnik. Wahrend es eine umfangreiche Literatur zum qualitativen Nachweis chemischer Substanzen mittels DC gibt, liegt der Fokus in diesem Buch bei der quantitativen Analyse."